Urology · Syracuse, NY
NPI
1376530121
Since 2005
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1226 E Water St
Syracuse, NY, 13210
Phone (315) 478-4185
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
32,166 services
Medicare patients, 2024
1,125
Average age 75
Drug cost, 2024
$10.9M
2,459 prescriptions
Company payments, 2025
$275K
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher M Pieczonka was code J0897 (injection, denosumab, 1 mg), 19,560 times for 66 patients. In total Christopher M Pieczonka billed 32,166 services in 65 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 19,560 | 66 | $20.48 | $401K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 4,326 | 80 | $45.02 | $195K |
| 36415 Venipuncture Blood Collection | Office | 979 | 665 | $8.40 | $8,220 |
| 81003 Clinical Chemistry | Office | 921 | 529 | $2.19 | $2,020 |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 850 | 12 | $2.27 | $1,930 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 600 | 338 | $11.82 | $7,092 |
| 99214 Office E&M - Established | Office | 556 | 308 | $90.01 | $50K |
| 99213 Office E&M - Established | Office | 456 | 313 | $61.08 | $28K |
| A9595 Piflufolastat f-18, diagnostic, 1 millicurie | Office | 288 | 30 | $502.03 | $145K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 239 | 30 | $43.12 | $10K |
| 96372 Injection Administration | Office | 183 | 65 | $10.91 | $1,997 |
| 96402 Chemotherapy Administration | Office | 144 | 101 | $26.29 | $3,785 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 116 | 20 | $138.74 | $16K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 100 | 15 | $42.17 | $4,217 |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 68 | 67 | $47.10 | $3,203 |
By year: 2022 $1.4M for 25,064 services; 2023 $1.2M for 32,069 services; 2024 $1.5M for 32,166 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 979 | 665 | $8.40 | $8,220 |
| 81003 Clinical Chemistry | 921 | 529 | $2.19 | $2,020 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher M Pieczonka prescribed most often to Medicare patients was Orgovyx (Relugolix), with 359 prescriptions and refills. In total Christopher M Pieczonka wrote 2,459 Medicare prescriptions that cost $10.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Orgovyx Relugolix | 359 | 367 | 52 | $995K |
| Tamsulosin Hcl Generic | 242 | 622 | 72 | $3,853 |
| Abiraterone Acetate Generic | 231 | 241 | 25 | $606K |
| Nubeqa Darolutamide | 193 | 199 | 23 | $2.5M |
| Erleada Apalutamide | 186 | 192 | 26 | $2.7M |
| Xtandi Enzalutamide | 182 | 208 | 24 | $3.0M |
| Prednisone Generic | 144 | 228 | 27 | $775 |
| Finasteride Generic | 135 | 399 | 44 | $2,234 |
| Silodosin Generic | 119 | 279 | 33 | $11K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 108 | 236 | 25 | $2,406 |
| Dutasteride Generic | 105 | 297 | 29 | $3,989 |
| Gemtesa Vibegron | 62 | 159 | 20 | $73K |
| Yonsa Abiraterone Acet,submicronized | 56 | 56 | Under 11 | $532K |
| Gabapentin Generic | 38 | 52 | Under 11 | $261 |
| Methylprednisolone Generic | 31 | 33 | Under 11 | $427 |
Brand drugs: 1,084 claims; generic drugs: 1,375 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher M Pieczonka $275K ($222K in general payments such as food, travel and fees and $54K for research) from 35 companies. The largest payer was Janssen Biotech, Inc. with $87K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 74 | $87K |
| Immunitybio, Inc. IBRX | 20 | $75K |
| Dendreon Pharmaceuticals LLC | 47 | $51K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 16 | $22K |
| Astellas Pharma US Inc 4503.T | 13 | $8,411 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $7,815 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 8 | $6,934 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $6,092 |
| Pfizer Inc. PFE | 13 | $4,058 |
| Merck Sharp & Dohme LLC MRK | 4 | $2,425 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.